Skip to main content
. 2022 Jun 14;10(4):e00926-22. doi: 10.1128/spectrum.00926-22

FIG 5.

FIG 5

The distribution of fold changes in IC50s relative to the normalized median IC50 for all authorized MAbs against wild-type variants (A) and the distribution of fold reductions in susceptibility (Omicron variant IC50/wild-type control IC50) relative to the normalized median fold reduction for all authorized MAbs (B). Results that were more than 4-fold (2−2) below or 4-fold (22) above the median result for an MAb were classified as outliers.